|
|
Article: Aldagen Announces Texas Heart Institute as First Site in its Stem Cell Clinical Trial to Treat Critical Limb Ischemia.
- Article from:
- PR Newswire
- Article date:
- December 15, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
DURHAM, N.C., Dec. 15 /PRNewswire/ -- Aldagen, Inc. today announced that the Texas Heart Institute at St. Luke's Episcopal Hospital in Houston, Texas will be the first site for its clinical trial using Aldagen's ALDESORT(R) product to isolate a unique stem cell population as therapy for critical limb ischemia (CLI) patients. The co-lead investigators at Texas Heart Institute on the study will be Dr. Emerson Perin and Dr. James Willerson.
"We are very excited to begin this study as it represents the first clinical study in the United States to use purified stem cells for the treatment of critical limb ischemia. We believe that these cells have the potential to ...